Meeting
2011 ASCO Annual Meeting
Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).
Authors
J. Lee
Molecular Signaling Section, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
J. Lee , C. M. Annunziata , L. M. Minasian , J. Zujewski , S. A. Prindiville , H. L. Kotz , J. Squires , N. D. Houston , J. J. Ji , M. Yu , J. H. Doroshow , E. C. Kohn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
Track
Developmental Therapeutics
Sub Track
Pharmacology
Clinical Trial Registration Number
NCT00647062
Citation
J Clin Oncol 29: 2011 (suppl; abstr 2520)
Abstract #
2520
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062).
First Author: Jung-min Lee
Poster
2019 ASCO Annual Meeting
Evolve: A post PARP inhibitor clinical translational Phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.
First Author: Stephanie Lheureux
Poster
2019 ASCO Annual Meeting
Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.
First Author: Junning Cao
Poster
2015 ASCO Annual Meeting
A phase 1 study optimizing the dosing of olaparib tablet formulation combined with cediranib in recurrent ovarian cancer.
First Author: Joyce Liu